{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:09:42Z","timestamp":1793441382061,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-21244-8","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T19:18:59Z","timestamp":1737487139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The epidemiology and unmet need of migraine in five european countries: results from the national health and wellness survey"],"prefix":"10.1186","volume":"25","author":[{"given":"Gianluca","family":"Coppola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Drakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Sternbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Hygge","family":"Blakeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"21244_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"21244_CR2","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163:e293\u2013309.","journal-title":"Pain"},{"key":"21244_CR3","unstructured":"Institute for Health Metrics and Evaluation. Headache disorders \u2014 Level 3 cause. 2020. https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/headache-disorders-level-3-cause. Accessed 27 Apr 2023."},{"key":"21244_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137.","journal-title":"J Headache Pain"},{"key":"21244_CR5","unstructured":"European Migraine & Headache Alliance. Migraine in the EU: Bringing women out of the shadows. 2021. 2021. https:\/\/www.emhalliance.org\/wp-content\/uploads\/Women-M-Policy-Paper-FINAL23MARCH.pdf?utm_campaign=further_reading. Accessed 26 Apr 2023."},{"key":"21244_CR6","unstructured":"European Brain Council. Rethinking migraine in times of COVID-19. https:\/\/www.braincouncil.eu\/wp-content\/uploads\/2022\/06\/RETHINKING-Migraine_report_V5_17062022.pdf. Accessed 3 May 2023."},{"key":"21244_CR7","doi-asserted-by":"publisher","first-page":"800605","DOI":"10.3389\/fneur.2021.800605","volume":"12","author":"P Amiri","year":"2022","unstructured":"Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, et al. Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022;12:800605.","journal-title":"Front Neurol"},{"key":"21244_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/0333102420974362","volume":"41","author":"DS van Casteren","year":"2021","unstructured":"van Casteren DS, Verhagen IE, Onderwater GL, MaassenVanDenBrink A, Terwindt GM. Sex differences in prevalence of migraine trigger factors: a cross-sectional study. Cephalalgia. 2021;41:643\u20138.","journal-title":"Cephalalgia"},{"key":"21244_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe \u2013 evidence from the Eurolight study. J Headache Pain. 2018;19:10.","journal-title":"J Headache Pain"},{"key":"21244_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache J Head Face Pain. 2018;58:17\u201332.","journal-title":"Headache J Head Face Pain"},{"key":"21244_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1129-2377-14-97","volume":"14","author":"JY Al-Hashel","year":"2013","unstructured":"Al-Hashel JY, Ahmed SF, Alroughani R, Goadsby PJ. Migraine misdiagnosis as a sinusitis, a delay that can last for many years. J Headache Pain. 2013;14:97.","journal-title":"J Headache Pain"},{"key":"21244_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S. Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19:82.","journal-title":"J Headache Pain"},{"key":"21244_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40120-020-00196-2","volume":"9","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Gupta S, Fang J, Laflamme AK, Vo P. The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther. 2020;9:535\u201349.","journal-title":"Neurol Ther"},{"key":"21244_CR14","unstructured":"European M. May & Headache Alliance. Migraine in Europe: Time to act now! https:\/\/www.emhalliance.org\/wp-content\/uploads\/EMHA-Call-to-Action-Final-1.pdf. Accessed 3 2023."},{"key":"21244_CR15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397:1505\u201318.","journal-title":"Lancet"},{"key":"21244_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener H-C, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501\u201314.","journal-title":"Nat Rev Neurol"},{"key":"21244_CR17","doi-asserted-by":"crossref","unstructured":"Vicente-Herrero MT, de la Ram\u00edrez-I\u00f1iguez MV, Ru\u00edz-de la Torre E, Reinoso-Barbero L. Preventive treatment in migraine. Used drugs and related variables. Results of the European work and migraine survey. Rev Mex Neurocienc. 2020;21.","DOI":"10.24875\/RMN.20000089"},{"key":"21244_CR18","doi-asserted-by":"publisher","first-page":"e0211191","DOI":"10.1371\/journal.pone.0211191","volume":"14","author":"P Brusa","year":"2019","unstructured":"Brusa P, Allais G, Scarinzi C, Baratta F, Parente M, Rolando S, et al. Self-medication for migraine: a nationwide cross-sectional study in Italy. PLoS ONE. 2019;14:e0211191.","journal-title":"PLoS ONE"},{"key":"21244_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P. Unmet needs in preventive treatment of migraine. Neurol Ther. 2023;12:337\u201342.","journal-title":"Neurol Ther"},{"key":"21244_CR20","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1038\/s41598-022-08716-w","volume":"12","author":"M Groth","year":"2022","unstructured":"Groth M, Katsarava Z, Ehrlich M. Results of the gErman migraine PatIent survey on medical care and prOPhylactic treatment experience (EPISCOPE). Sci Rep. 2022;12:4589.","journal-title":"Sci Rep"},{"key":"21244_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10194-021-01236-4","volume":"22","author":"B Lenz","year":"2021","unstructured":"Lenz B, Katsarava Z, Gil-Gouveia R, Karelis G, Kaynarkaya B, Meksa L, et al. Headache service quality evaluation: implementation of quality indicators in primary care in Europe. J Headache Pain. 2021;22:33.","journal-title":"J Headache Pain"},{"issue":"Suppl 3","key":"21244_CR22","first-page":"73","volume":"25","author":"C Strader","year":"2016","unstructured":"Strader C, Goren A, Dibonaventura M. 118. Prevalence of combinations of diabetes complications across NHANES and NHWS. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 3):73\u20134.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"21244_CR23","unstructured":"National Health and Wellness Survey (NHWS). https:\/\/www.cernerenviza.com\/real-world-data\/national-health-and-wellness-survey-nhws. Accessed 28 Mar 2023."},{"key":"21244_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"W Stewart","year":"2000","unstructured":"Stewart W, Lipton R, Kolodner K, Sawyer J, Lee C, Liberman J. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41\u201352.","journal-title":"Pain"},{"key":"21244_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jns.2016.11.071","volume":"372","author":"YW Woldeamanuel","year":"2017","unstructured":"Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307\u201315.","journal-title":"J Neurol Sci"},{"key":"21244_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/323084","volume":"2014","author":"J Matias-Guiu","year":"2014","unstructured":"Matias-Guiu J, Fernandez C, Porta-Etessam J, Mateos V, Diaz-Insa S. Factors associated with the differences in migraine prevalence rates between Spanish regions. Sci World J. 2014;2014:1\u20136. https:\/\/doi.org\/10.1155\/2014\/323084","journal-title":"Sci World J"},{"key":"21244_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10194-010-0223-2","volume":"11","author":"S Prakash","year":"2010","unstructured":"Prakash S, Mehta NC, Dabhi AS, Lakhani O, Khilari M, Shah ND. The prevalence of headache may be related with the latitude: a possible role of vitamin D insufficiency? J Headache Pain. 2010;11:301\u20137.","journal-title":"J Headache Pain"},{"key":"21244_CR28","unstructured":"World Health Organization. Headache disorders. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/headache-disorders#:~:text=Migraine%20most%20often%20begins%20at,between%2035%20and%2045%20years. Accessed 10 May 2023."},{"key":"21244_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s41687-020-00221-w","volume":"4","author":"JH Ford","year":"2020","unstructured":"Ford JH, Foster SA, Nichols RM, Tockhorn-Heidenreich A, Ye W, Jackson J, et al. A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. J Patient-Reported Outcomes. 2020;4:53.","journal-title":"J Patient-Reported Outcomes"},{"key":"21244_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40120-020-00205-4","volume":"9","author":"S Wongsiriroj","year":"2020","unstructured":"Wongsiriroj S, Grillo E, Levi S, Zielman R, Lahouiri E, Marchina M, et al. Management of migraine and the accessibility of specialist care: findings from an extended multinational survey (My Migraine Center Survey). Neurol Ther. 2020;9:551\u201365.","journal-title":"Neurol Ther"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-21244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-21244-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-21244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T19:19:05Z","timestamp":1737487145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-21244-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21244"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-21244-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and questionnaire for the NHWS were reviewed by the Pearl Institutional Review Board and were granted an exemption from review. Potential respondents were invited to complete the survey via an email invitation. Respondents who clicked the email link from their invitation were then directed to an informed consent statement and, if they provided consent, were provided screening questions to assess eligibility.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JB, ARM, AJ, and KHB are employees of Pfizer, Inc. SD and NS are employees of Oracle Life Sciences, which was a paid consultant to Pfizer to conduct the study and to develop the manuscript. ARM was an employee of Oracle Life Sciences at the time of this study. AG reports financial support for ad boards, consulting and speaker honoraria from: Gr\u00fcnenthal, Mundipharma, Abbvie\/Allergan, Lilly, Teva, Amgen, Novartis, Hormosan, Stada, Lundbeck, Pfizer, Hexal, Esanumperfood, Medscape, streamed up, \u00c4rztekammer Nordrhein, \u00c4rztekammer Westfalen Lippe, DGS, Regionalbeauftragte der DMKG. GC has received honoraria for participation in clinical trials and contribution to advisory boards or presentations from TEVA, Biohaven, Eli Lilly, Abbvie, and Pfizer. He serves as an Associate Editor for Cephalalgia, BMC Neurology \u2013 Pain section, Frontiers in Neurology \u2013 Neurotechnology section, Frontiers in Human Neuroscience \u2013 Brain Imaging and Stimulation section, and on the Advisory Board of The Journal of Headache and Pain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}